Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?
Acta Neuropathologica Communications volume 2, Article number: 6 (2014)
Recently heterozygous mutations in the active site of the enzyme isocitrate dehydrogenase 1 (IDH1) were discovered in glioblastomas . In cohorts of glioma patients the IDH1 mutation appeared to be a strong predictor of clinical outcome, overruling histological malignancy grade . IDH1 is an enzyme of the tricarboxylic acid (TCA) cycle and is located in the cytosol, where it produces NADPH by transforming isocitrate into α-ketoglutarate. Because the mutant enzyme displays neomorphic activity through NADPH-dependent transformation of α-ketoglutarate into 2-hydroxyglutarate (2HG), the tumorigenic role of the increased levels of 2HG has become a target of speculation . IDH1 mutation alters the cellular metabolism and epigenetic phenotype influencing cellular proliferation. IDH1 mutation infers increased levels of D2HGDH leading to the inhibition of DNA and histone demethylating enzymes, resulting in the glioma-CpG island phenotype . Altered concentrations of pyruvate kinase M2 play also a role in histone modifications which are associated with the transcription of the proliferation-related cyclin D1 and c-MYC . In addition, IDH1 mutant cells show alterations in glutamine, fatty acid and citrate synthesis pathways, which all may have their influence on cellular proliferation .
The changes in IDH1 function affect the glucose metabolism, which may explain the different biological behaviour of tumors with and without the IDH1 mutation . In order to detect these changes, we compared the expression levels of the genes participating in the TCA cycle and in the anaerobic glycolysis in 33 IDH1 mutated samples (3 astrocytomas WHO grade II; 6 astrocytomas WHO grade III; 4 glioblastomas; 9 oligodendrogliomas WHO grade II; 11 oligodendrogliomas WHO grade III) and in 39 IDH1 wild-type glioma samples (10 astrocytomas WHO grade III; 26 glioblastomas; 1 oligodendroglioma WHO grade II; 2 oligodendroglioma WHO grade III) and in four samples of normal brain (Table 1). We found expressional differences of 16/24 genes (Figure 1). The IDH1 mutated cells seem to compensate for the low production of α-ketoglutarate by overexpressing D2HGDH and L2HGDH in the cytoplasm. They also overexpress GLUD1, which converts glutamate to α-ketoglutarate inside the mitochondria. In addition, we found that IDH1 mutated cells overexpress HIF1AN. The HIF1AN gene inhibits HIF1α. Since HIF1α acts as an oxygen sensor that promotes angiogenesis, the formation of dysfunctional tumor vasculature is counteracted in IDH1 mutated cells. Furthermore, the IDH1 mutated cells overexpress the LDHB gene while cells without IDH1 mutation overexpress the LDHA gene. The present results illustrate that tumor cells without IDH1 mutation switch their energy production from a low rate of glycolysis followed by the TCA cycle to a high rate of glycolysis followed by aerobic glycolysis (LDHA up-regulation; Figure 1). The resulting lactate acid production causes tissue acidosis known as the Warburg effect. In invasive cancers, the pH of the extracellular space increases the infiltrative potential of the tumor cells . In addition, normalization of the extracellular pH by alterations of the enzymatic actions of LDHA and LDHB influences the progression of cancer cells [8, 9]. It may well be that glial tumor cells with IDH1 mutation tend to correct their energy production through the TCA cycle by overexpressing LDHB (Figure 1). By doing so, they normalize the tissue pH which offers yet another explanation for the less aggressive biological behavior of the IDH1 mutated gliomas.
We conclude that gliomas with IDH1 mutation normalize their glucose metabolism, which appears to result in a slower tumor progression. Depending on the IDH1 status of the tumor, specific interference with the glucose metabolism and aerobic glycolysis should therefore be considered for future therapeutic strategies.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al.: An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321: 1807–1812. 10.1126/science.1164382
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al.: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360: 765–773. 10.1056/NEJMoa0808710
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al.: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462: 739–744. 10.1038/nature08617
Borodovsky A, Seltzer MJ, Riggins GJ: Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Curr Opin Oncol 2012, 24: 83–89. 10.1097/CCO.0b013e32834d816a
Venneti S, Thompson CB: Metabolic modulation of epigenetics in gliomas. Brain Pathol 2013, 23: 217–221. 10.1111/bpa.12022
Reitman ZJ, Yan H: Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010, 102: 932–941. 10.1093/jnci/djq187
Mirebeau-Prunier D, Le Pennec S, Jacques C, Fontaine JF, Gueguen N, Boutet-Bouzamondo N, et al.: Estrogen-related receptor alpha modulates lactate dehydrogenase activity in thyroid tumors. PLoS One 2013, 8: e58683. 10.1371/journal.pone.0058683
Ho J, de Moura MB, Lin Y, Vincent G, Thorne S, Duncan LM, et al.: Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer 2012, 11: 76. 10.1186/1476-4598-11-76
McCleland ML, Adler AS, Deming L, Cosino E, Lee L, Blackwood EM, et al.: Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin Cancer Res 2013, 19: 773–784. 10.1158/1078-0432.CCR-12-2638
The authors thank Mr. M. van der Weiden for his technical assistance and Mr. F. van der Panne for assistance with the photography.
All authors declare that they have no competing interests.
DM and LB carried out the molecular genetic analyses; SS and PvdS carried out the data analysis and DM and JMK conceptualized and designed the study and wrote the manuscript. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
N Mustafa, D.A., Swagemakers, S.M., Buise, L. et al. Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?. acta neuropathol commun 2, 6 (2014). https://doi.org/10.1186/2051-5960-2-6